PBAC's latest decision on Terbutaline: Recommended (2020). Considered for Management of bronchospasm in patients unable to achieve coordinated use of a metered dose inhaler containing a short-acting beta-2 agonist, or in patients who have developed a clinically important product-related adverse event during treatment with another short-acting beta-2 agonist.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
first 2019
Submissions
2
2019 → 2020
Eligible population
Patients unable to achieve coordinated use of a metered dose inhaler containing a short-acting beta-2 agonist, or patients who have developed a clinically important product-related adverse event during treatment with another short-acting beta-2 agonist.
Therapy area
Respiratory
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
M2 Turbuhaler
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated as M3 Turbuhaler is therapeutically equivalent to M2 Turbuhaler.
Submission history
Jul 2019: Recommended with restriction · Authority Required